Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment

被引：4
|
作者：
Sasse, Stephanie [1 ,2 ]
Reddemann, Katharina [3 ]
Diepstra, Arjan [4 ]
Borchmann, Sven [1 ,2 ,5 ,6 ]
Oschlies, Ilske [3 ]
Schnitter, Antje [3 ]
Engert, Andreas [1 ,2 ]
Borchmann, Peter [1 ,2 ]
Klapper, Wolfram [3 ]
机构：
[1] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[2] Univ Hosp Cologne, German Hodgkin Study Grp, Cologne, Germany
[3] Univ Kiel, Univ Hosp Schleswig Holstein, Hematopathol Sect, Dept Pathol, Kiel, Germany
[4] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands
[5] Univ Hosp Cologne, Ctr Mol Med, Cologne, Germany
[6] Univ Cologne, Else Kroner Forsch Kolleg Cologne, Cologne, Germany
来源：
HAEMATOLOGICA | 2019年 / 104卷 / 01期
关键词：
D O I：
10.3324/haematol.2018.207829
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E45 / E46
页数：2
相关论文
共 50 条
  • [21] The programmed cell death protein 1 (PD1) and the programmed cell death ligand 1 (PD-L1) are significantly downregulated on macrophages and Hofbauer cells in the placenta of preeclampsia patients
    Mittelberger, Johanna
    Seefried, Marina
    Loeb, Sanja
    Kuhn, Christina
    Franitza, Manuela
    Garrido, Fabian
    Wild, Carl Mathis
    Ditsch, Nina
    Jeschke, Udo
    Dannecker, Christian
    JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2023, 157
  • [22] Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort
    Merryman, Reid W.
    Castagna, Luca
    Corradini, Paolo
    Ho, Vincent T.
    Bond, David A.
    Jaglowski, Samantha
    Spinner, Michael A.
    Arai, Sally
    Lowsky, Robert
    Herrera, Alex F.
    Guidetti, Anna
    Shouse, Geoffrey
    Blaise, Didier
    De Colella, Jean Marc Schiano
    Badar, Talha
    Hamadani, Mehdi
    Ansell, Stephen M.
    Nieto, Yago
    Spilleboudt, Chloe
    Feldman, Tatyana A.
    Dahncke, Lori
    Singh, Anurag K.
    McGuirk, Joseph P.
    Mohty, Mohamad
    Dulery, Remy
    Bastard, Aspasia Stamatoulas
    Houot, Roch
    Manson, Guillaume
    Moles, Marie-Pierre
    Orvain, Corentin
    Bouabdallah, Kamal
    Frigault, Matthew J.
    Chen, Yi-Bin
    Lynch, Ryan C.
    Smith, Stephen D.
    Rao, Uttam
    Byrne, Michael T.
    Romancik, Jason
    Cohen, Jonathon B.
    Joyce, Robin M.
    Rahimian, Maryam
    Bashey, Asad
    Ballard, Hatcher J.
    Svoboda, Jakub
    Giordano, Laura
    Torri, Valter
    Casadei, Beatrice
    Sollini, Martina
    De Philippis, Chiara
    Magagnoli, Massimo
    BLOOD, 2019, 134
  • [23] Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma
    Koh, Young Wha
    Jeon, Yoon Kyung
    Yoon, Dok Hyun
    Suh, Cheolwon
    Huh, Jooryung
    TUMOR BIOLOGY, 2016, 37 (06) : 7507 - 7514
  • [24] Binding Free Energy Analysis of Programmed Cell Death Protein PD1 to its Ligand PD-L1
    Pan, Peter C.
    Tafazzol, Alireza
    Zhang, Xianwei
    Duan, Yong
    BIOPHYSICAL JOURNAL, 2019, 116 (03) : 477A - 477A
  • [25] BINDING FREE ENERGY ANALYSIS OF PROGRAMMED CELL DEATH PROTEIN PD1 TO ITS LIGAND PD-L1
    Pan, Peter
    Tafazzol, Alireza
    Zhang, Xianwei
    Duan, Yong
    NEURO-ONCOLOGY, 2018, 20 : 67 - 67
  • [26] Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma
    Paydas, Semra
    Bagir, Emine
    Seydaoglu, Gulsah
    Ercolak, Vehbi
    Ergin, Melek
    ANNALS OF HEMATOLOGY, 2015, 94 (09) : 1545 - 1552
  • [27] Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma
    Semra Paydas
    Emine Bağır
    Gulsah Seydaoglu
    Vehbi Ercolak
    Melek Ergin
    Annals of Hematology, 2015, 94 : 1545 - 1552
  • [28] Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1
    Reinke, Sarah
    Broeckelmann, Paul J.
    Iaccarino, Ingram
    Garcia-Marquez, Maria
    Borchmann, Sven
    Jochims, Franziska
    Kotrova, Michaela
    Pal, Karol
    Brueggemann, Monika
    Hartmann, Elena
    Sasse, Stephanie
    Kobe, Carsten
    Mathas, Stephan
    Soekler, Martin
    Keller, Ulrich
    Bormann, Matthias
    Zimmermann, Andreas
    Richter, Julia
    Fuchs, Michael
    von Tresckow, Bastian
    Borchmann, Peter
    Schloesser, Hans
    von Bergwelt-Baildon, Michael
    Rosenwald, Andreas
    Engert, Andreas
    Klapper, Wolfram
    BLOOD, 2020, 136 (25) : 2851 - 2863
  • [29] Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma
    Ogasawara, Reiki
    Hashimoto, Daigo
    Sugita, Junichi
    Yamawaki, Fumihiko
    Naka, Tomoaki
    Mitsuhashi, Tomoko
    Takahashi, Shuichiro
    Miyashita, Naohiro
    Okada, Kohei
    Onozawa, Masahiro
    Matsuno, Yoshihiro
    Teshima, Takanori
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (03) : 475 - 479
  • [30] Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma
    Reiki Ogasawara
    Daigo Hashimoto
    Junichi Sugita
    Fumihiko Yamawaki
    Tomoaki Naka
    Tomoko Mitsuhashi
    Shuichiro Takahashi
    Naohiro Miyashita
    Kohei Okada
    Masahiro Onozawa
    Yoshihiro Matsuno
    Takanori Teshima
    International Journal of Hematology, 2020, 111 : 475 - 479
12345